Progress in Gynecologic Cancer Research: The Gynecologic Oncology Group Experience

Seminars in Oncology

Volumn 35, Issue 5, 2008, Pages 507-521

  Omura, George A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; BCG VACCINE; BLEOMYCIN; CARBOPLATIN; CHLORAMBUCIL; CHLORMETHINE DERIVATIVE; CHROMIUM PHOSPHATE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; MELPHALAN; METHOTREXATE; MISONIDAZOLE; PACLITAXEL; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ADJUVANT THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; DRUG DOSE COMPARISON; ENDOMETRIUM CANCER; GERM CELL TUMOR; GRANULOSA CELL TUMOR; GYNECOLOGIC CANCER; HEALTH CARE; HEALTH CARE MANAGEMENT; HEALTH CARE ORGANIZATION; HUMAN; IRRADIATION; LAPAROSCOPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; REMISSION; STROMA; TROPHOBLASTIC TUMOR; UTERINE CERVIX CANCER; UTERUS SARCOMA; VULVA CARCINOMA;

CLINICAL TRIALS, PHASE III AS TOPIC; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MEDICAL ONCOLOGY; OVARIAN NEOPLASMS; RESEARCH; UTERINE CERVICAL NEOPLASMS;

EID: 53149085942     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.07.007     Document Type: Article

References (121)

1. Sutton G.P., Bundy B.N., Omura G.A., et al. Stage III ovarian tumors of low malignant potential treated with cisplatin-combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol. 41 (1991) 230-233
2. Barnhill D.R., Kurman R.J., Brady M.F., et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a GOG study. J Clin Oncol. 13 (1995) 2752-2756
3. Hreshchyshyn M.M., Park R.C., Blessing J.A., et al. The role of adjuvant therapy in stage I ovarian cancer (from the GOG). Am J Obstet Gynecol. 138 (1980) 139-145
4. Young R.C., Walton L.A., Ellenberg S.S., et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med. 322 (1990) 1021-1027
5. Buchsbaum H.J., Brady M.F., Delgado G., et al. Surgical staging of ovarian carcinoma: a GOG study. Surg Gynecol Obstet. 169 (1989) 226-232
6. Young R.C., Brady M.F., Nieberg R.K., et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32p or cyclophosphamide-cisplatin: a GOG study. J Clin Oncol. 21 (2003) 4350-4355
7. Trimbos J.B., Parmar M., Vergote I., et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 95 (2003) 105-112
8. Bell J., Brady M., Young R., et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage ovarian carcinoma: a GOG study. Gynecol Oncol. 102 (2006) 432-439
9. Markman M., Blessing J., Rubin S., et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a GOG study. Gynecol Oncol. 101 (2006) 436-440
10. Brady L.W., Blessing J.A., Slayton R.E., et al. Radiotherapy, chemotherapy and combined therapy in stage III epithelial ovarian cancer (for the GOG). Cancer Clin Trials 2 (1979) 111-120
11. Park R.C., Blom J., DiSaia P.J., et al. Treatment for women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin (from the GOG). Cancer 45 (1980) 2529-2542
12. Gall S., Bundy B., Beecham J., et al. Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan plus Corynebacterium parvum (a GOG study). Gynecol Oncol. 25 (1986) 26-36
13. Omura G.A., Morrow C.P., Blessing J.A., et al. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus Adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 51 (1983) 783-789
14. Wiltshaw E., and Kroner T. Phase II study of cis-dichlorodiammine-platinum(II)(NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep. 60 (1976) 55-60
15. Omura G., Blessing J.A., Ehrlich C.E., et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: a GOG study. Cancer 57 (1986) 1725-1730
16. Omura G.A., Brady M.F., Homesley H.D., et al. Long follow-up and prognostic factor analysis in advanced ovarian carcinoma: the GOG experience. J Clin Oncol. 9 (1991) 1138-1150
17. Omura G.A., Bundy B.N., Berek J.S., et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a GOG study. J Clin Oncol. 7 (1989) 457-465
18. The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol. 9 (1991) 1668-1674
19. duBois A., Weber B., Rochon J., et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol. 24 (2006) 1127-1135
20. Bookman M.A. ICON5: 5-arm phase III randomized trial of paclitaxel and carboplatin vs combinations with gemcitabine, PEG-liposomal doxorubicin, or topotecan in patients with advanced-stage epithelial ovarian or primary peritoneal carcinoma. [abstract]. J Clin Oncol. 24 Suppl (2006) 5002
21. Creasman W.T., Omura G., Brady M.F., et al. A randomized study of cyclophosphamide, doxorubicin and cisplatin with or without BCG in patients with suboptimal stage III and IV ovarian cancer: a GOG study. Gynecol Oncol. 39 (1990) 239-243
22. McGuire W.P., Hoskins W.J., Brady M.F., et al. Assessment of dose intense therapy in suboptimally debulked ovarian cancer: a GOG study. J Clin Oncol. 13 (1995) 1589-1599
23. Grenman S., Wiklund T., Jalkanen J., et al. A randomized phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study. Eur J Cancer 42 (2006) 2196-2199
24. Thigpen J.T., Blessing J.A., Ball H., et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a GOG study. J Clin Oncol. 12 (1994) 1748-1753
25. McGuire III W.P., Hoskins W.J., Brady M.F., et al. A phase III randomized study of cyclophosphamide and cisplatin versus paclitaxel and cisplatin in patients with suboptimal stage III and IV epithelial ovarian cancer. N Engl J Med. 334 (1996) 1-6
26. Piccart M.J., Bertelsen K., James K., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 92 (2000) 699-708
27. Muggia F.M., Braly P.S., Brady M.F., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a GOG study. J Clin Oncol. 18 (2000) 106-115
28. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 360 (2002) 505-515
29. Piccart M.J., Bertelsen K., Stuart G., et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 13 Suppl (2003) 144-148
30. Eisenhauer E.A., ten Bokkel Huinink W.W., Swenerton K.D., et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 12 (1994) 2654-2666
31. Omura G.A., Brady M.F., Look K.Y., et al. Phase III trial of a paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an Intergroup study (GOG, SWOG, NCCTG, ECOG). J Clin Oncol. 21 (2003) 2843-2848
32. Spriggs D., Brady M., Vacarello L., et al. A phase III randomized trial of IV cisplatin plus a 24-or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a GOG study. J Clin Oncol. 25 (2007) 4466-4471
33. Bookman M.A., McGuire III W.P., Kilpatrick D., et al. Carboplatin and paclitaxel in ovarian and peritoneal carcinoma: a phase I study of the GOG. J Clin Oncol. 14 (1996) 1895-1902
34. Ozols R., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a GOG study. J Clin Oncol. 21 (2003) 3194-3200
35. Greer B.E., Bundy B.N., Ozols R.F., et al. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using explanatory analysis (GOG protocol 158). Gynecol Oncol. 99 (2005) 71-79
36. Vasey P.A., Jayson G.C., Gordon A., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 96 (2004) 1682-1691
37. Pfisterer J., Weber B., Reuss A., et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 98 (2006) 1036-1045
38. Burger R.A., Sill M.W., Monk B.J., et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a GOG study. J Clin Oncol. 25 (2007) 5165-5171
39. Alberts D., Liu P.Y., Hannigan E.V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 335 (1996) 1950-1955
40. Markman M., Bundy B.N., Alberts D.S., et al. Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the GOG, SWOG, and ECOG. J Clin Oncol. 19 (2001) 1001-1007
41. Armstrong D.K., Bundy B.N., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354 (2006) 34-43
42. Walker J.L., Armstrong D., Huang H., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a GOG study. Gynecol Oncol. 100 (2006) 27-32
43. Wenzel L., Huang H., Armstrong D., et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a GOG study. J Clin Oncol. 25 (2007) 437-443
44. Ozols R.F., Bookman M.A., and Young R.C. Intraperitoneal chemotherapy for ovarian cancer. N Engl J Med. 354 (2006) 1641-1643
45. Varia M., Stehman F.B., Bundy B., et al. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the GOG. J Clin Oncol. 21 (2003) 2849-2855
46. Markman M., Liu P.Y., Wilczynski S., et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 21 (2003) 2460-2465
47. Rose P.G., Nerenstone S., Brady M., et al. Secondary surgical cytoreduction in advanced ovarian carcinoma: a GOG study. N Engl J Med. 351 (2004) 2489-2497
48. Wenzel L., Huang H., Monk B., et al. Quality of life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a GOG study. J Clin Oncol. 23 (2005) 5605-5612
49. Slayton R.E., Park R.C., Silverberg S.G., et al. Vincristine, dactinomycin and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary: a GOG study (a final report). Cancer 56 (1985) 243-248
50. Williams S., Blessing J.A., Moore D.H., et al. Cisplatin, vinblastine, and bleomycin in recurrent ovarian germ cell tumors: a trial of the GOG. Ann Intern Med. 3 (1989) 22-27
51. Williams S.D., Blessing J.A., Hatch K.D., et al. Chemotherapy of advanced dysgerminoma: trials of the GOG. J Clin Oncol. 9 (1991) 1950-1955
52. Williams S.D., Blessing J.A., DiSaia P.J., et al. Second-look laparotomy in ovarian germ cell tumors: the GOG experience. Gynecol Oncol. 52 (1994) 287-291
53. Homesley H.D., Bundy B.N., Hurteau J.A., et al. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a GOG study. Gynecol Oncol. 72 (1999) 131-137
54. Morrow C.P., Bundy B.N., Hoffman J., et al. Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary (A GOG study). Am J Clin Oncol CCT 9 (1986) 24-26
55. Thigpen J.T., Blessing J.A., DeGeest K., et al. Cisplatin as initial therapy in ovarian carcinosarcomas: a GOG study. Gynecol Oncol. 93 (2004) 336-339
56. Boronow R.C., Morrow C.P., Creasman W.T., et al. Surgical staging in endometrial cancer: 1. Clinical-pathologic findings of a prospective study. Obstet Gynecol. 63 (1984) 825-832
57. Creasman W.T., DeGeest K., DiSaia P.J., et al. Significance of true surgical pathologic staging: a GOG study. Am J Obstet Gynecol. 181 (1999) 31-34
58. Morrow C.P., Bundy B., Kurman R., et al. Relationship between surgical-pathological risk factors and outcome in clinical stages I and II carcinoma of the endometrium (a GOG study). Gynecol Oncol. 40 (1991) 55-65
59. Homesley H.D., Boike G., and Spiegel G.W. Feasibility of laparoscopic management of presumed stage I endometrial carcinoma and assessment of accuracy of myoinvasion estimates by frozen section: a GOG study. Int J Gynecol Cancer 14 (2004) 341-347
60. Keys H.M., Roberts J.A., Brunetto V.L., et al. A phase III trial of surgery with or without adjunctive external pelvic irradiation therapy in intermediate risk endometrial adenocarcinoma: a GOG study. Gynecol Oncol. 92 (2004) 744-751
61. Randall M., Filiaci V., Muss H., et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a GOG study. J Clin Oncol. 24 (2006) 36-44
62. Thigpen J.T., Brady M.F., Homesley H., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a GOG study. J Clin Oncol. 22 (2004) 3902-3908
63. Bruner DW, Barsevick A, Tian C, et al. Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: a GOG study. Qual Life Res. 207;16:89-100.
64. Maggi R., Lissoni A., Spina F., et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomized trial. Br J Cancer 95 (2006) 266-271
65. Thigpen J.T., Brady M.F., Alvarez R.D., et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the GOG. J Clin Oncol. 17 (1999) 1736-1744
66. Whitney C.W., Brunetto V.L., Zaino R., et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a GOG study. Gynecol Oncol. 92 (2004) 4-9
67. Fiorica J.V., Brunetto V.L., Hanjani P., et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a GOG study. Gynecol Oncol. 92 (2004) 10-14
68. Cohen C.J., Bruckner H.W., Deppe G., et al. Multidrug treatment of advanced and recurrent endometrial carcinoma: a GOG study. Obstet Gynecol. 63 (1984) 719-726
69. Thigpen J.T., Blessing J.A., DiSaia P.J., et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a GOG study. J Clin Oncol. 12 (1994) 1408-1414
70. Morrow C.P., Bundy B.N., Homesley H.D., et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a GOG study. Gynecol Oncol. 36 (1990) 166-171
71. Gallion H.H., Brunetto V.L., Cibull M., et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 21 (2003) 3808-3813
72. Fleming G.F., Filiaci V.L., Bentley R., et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-hour paclitaxel + filgrastim in endometrial carcinoma: a GOG study. Ann Oncol. 15 (2004) 1173-1178
73. Fleming G.F., Brunetto V.L., Cella D., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a GOG study. J Clin Oncol. 22 (2004) 2159-2166
74. Major F.J., Blessing J.A., Silverberg S.G., et al. Prognostic factors in early-stage uterine sarcoma: a GOG study. Cancer 71 (1993) 1702-1709
75. Omura G.A., Major F.J., Blessing J.A., et al. A randomized study of Adriamycin with and without dimethyl triazenimidazole carboxamide in advanced uterine sarcomas. Cancer 52 (1983) 626-632
76. Omura G.A., Major F.J., Lifshitz S., et al. A randomized clinical trial of adjuvant Adriamyin in uterine sarcomas: a GOG study. J Clin Oncol. 3 (1985) 1240-1245
77. Sarcoma Meta-Analysis Collaboration. Adjuvant chemotherapy for locally resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 350 (1997) 1647-1654
78. Hornback N.B., Omura G., and Major F.J. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys. 12 (1986) 2127-2130
79. Muss H.B., Bundy B.N., DiSaia P.J., et al. Treatment of recurrent or advanced uterine sarcoma: a randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the GOG). Cancer 55 (1985) 1648-1653
80. Sutton G., Brunetto V.L., Kilgore L., et al. A phase III trial of ifosfamide with or without cisplatin in carcinoma of the uterus: a GOG study. Gynecol Oncol. 79 (2000) 147-153
81. Homesley H.D., Filiaci V.L., Markman M., et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine sarcoma: a Gynecologic Oncology Group study. J Clin Oncol. 25 (2007) 526-531
82. Wolfson A.E., Brady M.F., Mannel R.S., et al. A Gynecologic Oncology Group randomized trial of whole abdominal irradiation versus cisplatin-ifosfamide+mesma in optimally debulked stage I-IV carcinosarcoma of the uterus. Gynecol Oncol. 107 (2007) 177-185
83. Curry S.L., Schlaerth J.B., Kohorn E.I., et al. Hormonal contraception and trophoblastic sequelae after hydatidiform mole. Am J Obstet Gynecol. 160 (1989) 805-811
84. Curry S.L., Blessing J.A., DiSaia P.J., et al. A prospective randomized comparison of methotrexate, dactinomycin and chlorambucil versus methotrexate, dactinomycin cyclophosphamide, doxorubicin, melphalan, hydroxyurea and vincristine in "poor prognosis" metastatic gestational trophoblastic disease (a GOG study). Obstet Gynecol. 73 (1989) 357-362
85. Delgado G., Bundy B.N., Fowler W.C., et al. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a GOG study. Gynecol Oncol. 35 (1989) 314-320
86. Delgado G., Bundy B., Zaino R., et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a GOG study. Gynecol Oncol. 38 (1990) 352-357
87. Keys H., Bundy B.N., Stehman F.B., et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical cancer: a randomized trial of the GOG. Gynecol Oncol. 89 (2003) 343-353
88. Sedlis A., Bundy B.N., Rotman M.Z., et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a GOG study. Gynecol Oncol. 73 (1999) 177-183
89. Rotman M., Sedlis A., Piedmonte M.R., et al. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: followup of a GOG study. Int J Radiat Oncol Biol Phys. 65 (2006) 169-176
90. Hreshchyshyn M.M., Aron B.S., Boronow R.C., et al. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys. 5 (1979) 317-322
91. Symonds R.P., Collingwood M., Kirwan J., et al. Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix: a systemic review. Cancer Treat Rev. 30 (2004) 405-414
92. Stehman F., Bundy B.N., Keys H., et al. A randomized trial of hydroxyurea versus misonidazole adjunct to radiation therapy in carcinoma of the cervix: a GOG study. Am J Obstet Gynecol. 159 (1988) 87-94
93. Whitney C.W., Sause W., Bundy B.N., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 17 (1999) 1339-1348
94. Peters III W.A., Liu P.Y., Barrett II R.J., et al. Concurrent chemotherapy and pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 18 (2000) 1606-1613
95. Keys H.M., Bundy B.N., Stehman F.B., et al. Weekly cisplatin chemotherapy during irradiation improves survival and reduces relapses for patients with bulky stage IB cervical cancer treated with irradiation and adjuvant hysterectomy: results of a randomized GOG trial. N Engl J Med. 340 (1999) 1154-1161
96. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 340 (1999) 1137-1143
97. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemoradiation for locally advanced cervical cancer: results of a randomized GOG study. N Engl J Med. 340 (1999) 1144-1153
98. Pearcey R., Brundage M., Drouin P., et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 20 (2002) 966-972
99. Lanciano R., Calkins A., Bundy B., et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a GOG study. J Clin Oncol. 23 (2005) 8289-8295
100. Wallace Jr. H.J., Hreshchyshyn M.M., Wilbanks G.D., et al. Comparison of the therapeutic effects of Adriamycin alone versus Adriamycin plus vincristine versus Adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat Rep. 62 (1978) 1434-1441
101. Bonomi P., Blessing J.A., Stehman F.B., et al. Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix (a GOG study). J Clin Oncol. 3 (1985) 1079-1085
102. Thigpen J.T., Blessing J.A., DiSaia, et al. A randomized comparison of a rapid versus prolonged (24 hour) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a GOG study. Gynecol Oncol. 32 (1989) 198-202
103. McGuire III W.P., Arseneau J., Blessing J.A., et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a GOG study. J Clin Oncol. 7 (1989) 1462-1468
104. Omura G.A., Blessing J.A., Vaccarello L., et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous cell carcinoma of the cervix: a GOG study. J Clin Oncol. 15 (1997) 165-171
105. Bloss J., Blessing J.A., Behrens B.C., et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a GOG study. J Clin Oncol. 20 (2002) 1832-1837
106. Moore D.H., Blessing J.A., McQuellon R.P., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a GOG study. J Clin Oncol. 22 (2004) 3113-3119
107. McQuellon R.P., Thaler H., Cella D., et al. Quality of life outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel for women with metastatic cervix cancer: results from the GOG study #169. Gynecol Oncol. 101 (2006) 296-304
108. Long H.J., Bundy B.N., Grendys E.C., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a GOG study. J Clin Oncol. 23 (2005) 4626-4633
109. Monk B.J., Huang H., Cella D., et al. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a GOG study. J Clin Oncol. 23 (2005) 4617-4625
110. Homesley H.D., Bundy B.N., Sedlis A., et al. A randomized study of radiation therapy versus pelvic node resection for patients with invasive squamous cell carcinoma of the vulva having positive groin nodes (a GOG study). Obstet Gynecol. 68 (1986) 733-740
111. Schilder R., Sill M., Chen X., et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a GOG study. Clin Cancer Res. 11 (2005) 5539-5548
112. Smith S., Richards W.E., Caito K., et al. BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a GOG study. Gynecol Oncol. 83 (2001) 586-592
113. Reedy M., Gallion H., Fowler J., et al. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a GOG study. Gynecol Oncol. 85 (2002) 255-259
114. Baysal B., DeLoia J., Willett-Brozick J., et al. Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol. 95 (2004) 62-69
115. Wilcox C.B., Baysal B.E., Gallion H.H., et al. High resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet. 159 (2005) 114-122
116. Havrilesky L., Darcy K.M., Hamdan H., et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a GOG study. J Clin Oncol. 21 (2003) 3814-3825
117. He X., Ee P.L.R., Coon J., et al. Alternative splicing of the mutlidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20(1). Clin Cancer Res. 10 (2004) 4652-4660
118. Burger R.A., Darcy K.M., DiSaia P.J., et al. Association between serum levels of soluble tumor necrosis factor receptors/CA125 and disease progression in patients with epithelial ovarian malignancy: a GOG study. Cancer 101 (2004) 106-115
119. Barakat R., Bundy B., Spirtos N., et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in women with stage I or II endometrial cancer: a GOG study. J Clin Oncol. 24 (2006) 587-592
120. Trimble C., Kauderer J., Zaino R., et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a GOG study. Cancer 106 (2006) 812-819
121. Zaino R., Kauderer J., Trimble C., et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a GOG study. Cancer 106 (2006) 804-811